Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high‐risk neuroblastoma: A case series |
| |
| Authors: | Yang‐Yang Ding Jessica Panzer John M Maris Alicia Castañeda Marta Gomez‐Chiari Jaume Mora |
| |
| Affiliation: | 1. Department of Pediatric Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania;2. Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania;3. Departments of Pediatric Heamtology and Oncology and radiology, Hospital Sant Joan de Deu, Barcelona, Spain |
| |
| Abstract: | ![]()
Immunotherapy with the anti‐GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high‐risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery. |
| |
| Keywords: | anti‐GD2 monoclonal antibody dinutuximab neuroblastoma transverse myelitis Unituxin |
|
|
